Skip to main content
Fig. 5 | BMC Neurology

Fig. 5

From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Fig. 5

Kaplan–Meier curves for overall survival of different FXYD2 mRNA expression in CGGA glioma patients with different histologic type, WHO classification, IDH mutation and 1p/19q col-deletion status. The Kaplan–Meier curves for overall survival of different FXYD2 mRNA expression in glioma patients with different WHO grade (A, B), histologic type (C, D), IDH mutation (E, F) and 1p/19q col-deletion status (G, H). Log rank test was used to compare the difference between the two survival curves

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us